Related Experiment Video
Updated: Jul 8, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase
Bruce Koppelman1, Heather K Webb, Satyanarayana Medicherla
1Scios, Inc., Fremont, Calif., USA. bruce_koppelman@yahoo.com
Abstract:
The effects of small-molecule p38 inhibitors in numerous models of different disease states have been published, including those of SD-282, an indole-5-carboxamide inhibitor. The aim of the present study was to evaluate the pharmacological activity of SD-282 on cytokine production in vitro as well as in 2 in vivo models of inflammation in order to illuminate the role of this particular inhibitor in diverse disease states. The results presented here provide further characterization of SD-282 and provide a context in which to interpret the activity of this p38 inhibitor in models of arthritis, pain, myocardial injury, sepsis and asthma; all of which have an inflammatory component. SD-282 represents a valuable tool to elucidate the role of p38 MAP kinase in multiple models of inflammation.
Related Concept Videos
MAPK Signaling Cascades
GPCRs Regulate Adenylyl Cylase Activity
Two...
The JAK-STAT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
